Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease
Preliminary results from the ongoing Brainshuttle™ AD study suggest that rapid and deep amyloid reduction can be achieved in most participants at 1.8 and 3.6 mg/kg doses within ≤28 weeks. New biomarker data will be presented to further evaluate trontinemab's continued development as a potential AD treatment.
Authors
- David J. Agnew (ORCID: https://orcid.org/0000-0003-0205-8145)
- Fabien Alcaraz
- Silke Ahlers
- Ruth Croney (ORCID: https://orcid.org/0009-0004-8176-3073)
- Luka Kulic (ORCID: https://orcid.org/0000-0003-3427-9436)
- Paul Delmar (ORCID: https://orcid.org/0000-0002-2095-6283)
- Hanno Svoboda (ORCID: https://orcid.org/0009-0005-1910-586X)
- Franziska Schaedeli Stark (ORCID: https://orcid.org/0009-0002-5692-3448)
- Daria Rukina
- Carsten Hofmann
- Jakub Wojtowicz (ORCID: https://orcid.org/0009-0007-6659-8008)
- Maddalena Marchesi
- Gregory Klein
- Tobias Bittner (ORCID: https://orcid.org/0000-0001-9256-0360)
- Iris Wiesel
- Henrik Zetterberg
- Gil D. Rabinovici
- Matteo Tonietto
- João A. Abrantes
Institutions
- Roche (Switzerland) (CH)
- University of California, San Francisco (US)
- Roche (United Kingdom) (GB)
- Excelitas Technologies (Germany) (DE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_104288
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16